Primary Epstein-Barr virus infection: Impact of age at acquisition, coinfection, and viral load

Journal of Infectious Diseases

Volumn 207, Issue 12, 2013, Pages 1787-1789

  Balfour, Henry H ^a   Verghese, Priya ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

coinfection; EBV viral load; Epstein Barr virus; HIV; malaria

Indexed keywords

EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AGE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EDITORIAL; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPATOSPLENOMEGALY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSURVEILLANCE; INFECTION CONTROL; LYMPHOPROLIFERATIVE DISEASE; MALARIA FALCIPARUM; MIXED INFECTION; MONONUCLEOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

EID: 84877934285     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit096     Document Type: Editorial

References (17)

1. Slyker JA, Casper C, Tapia K, et al. Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infectioninKenyan infants born to HIV-infected women. J Infect Dis 2013; 207:1798-806.
2. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J 2004; 23:536-43.
3. Gichuhi C, Obimbo E, Mbori-Ngacha D, et al. Predictors of mortality in HIV-1 exposed uninfected post-neonatal infants at the Kenyatta National Hospital, Nairobi. East Afr Med J 2005; 82:447-51.
4. Moormann AM, Chelimo K, Sumba OP, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005; 191:1233-8.
5. Piriou E, Asito AS, Sumba PO, et al. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis 2012; 205:906-13.
6. de-Thé G. Is Burkitt's lymphoma related to perinatal infection by Epstein-Barr virus? Lancet 1977; 1:335-8.
7. de-Thé G, Geser A, Day NE, et al. Epidemio-logical evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274: 756-61.
8. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, Kazura JW. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 2007; 195:799-808.
9. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1765-77.
10. Pohl D, Krone B, Rostasy K, et al. High seropre-valence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67:2063-5.
11. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6:773-81.
12. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346-53.
13. Mañez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovi-rus disease. J Infect Dis 1997; 176:1462-7.
14. Holman CJ, Karger AB, Mullan BD, Brund-age RC, Balfour HH Jr. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 2012; 26:741-7.
15. Balfour HH Jr, Odumade OA, Schmeling DO, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 2013; 207:80-8.
16. Sokal EM, Hoppenbrouwers K, Vandermeu-len C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196:1749-53.
17. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleo-sis-and what else? J Infect Dis 2007; 196: 1724-6.